Stoke Therapeutics, Inc.
STOK
$33.61
$0.631.91%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 117.25% | 186.01% | 3,661.12% | 707.07% | 47.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 117.25% | 186.01% | 3,661.12% | 707.07% | 47.94% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 117.25% | 186.01% | 3,661.12% | 707.07% | 47.94% |
| SG&A Expenses | 26.28% | 17.07% | 43.38% | 21.06% | 23.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.95% | 20.32% | 45.23% | 11.98% | 14.26% |
| Operating Income | -43.62% | 6.96% | 492.08% | 53.85% | -10.17% |
| Income Before Tax | -49.92% | 8.61% | 532.84% | 61.12% | -7.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.09% | 8.61% | 527.99% | 61.12% | -7.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.09% | 8.61% | 527.99% | 61.12% | -7.69% |
| EBIT | -43.62% | 6.96% | 492.08% | 53.85% | -10.17% |
| EBITDA | -44.75% | 6.74% | 501.73% | 54.68% | -10.78% |
| EPS Basic | -39.48% | 12.67% | 442.07% | 69.35% | 15.39% |
| Normalized Basic EPS | -44.10% | 12.67% | 445.99% | 69.34% | 15.38% |
| EPS Diluted | -39.21% | 12.67% | 433.16% | 69.35% | 15.22% |
| Normalized Diluted EPS | -44.10% | 12.67% | 437.04% | 69.34% | 15.38% |
| Average Basic Shares Outstanding | 4.03% | 4.64% | 25.12% | 26.85% | 27.28% |
| Average Diluted Shares Outstanding | 4.03% | 4.64% | 28.44% | 26.85% | 27.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |